BN Business News
Add your company to Business Communicator →

Regulation & law · 30/11/2018

National Cancer Institute Considers Exclusive Patent License to Bull Run Capital for Cancer Research

The National Cancer Institute, part of the National Institutes of Health, is evaluating a potential exclusive patent license to Bull Run Capital, a Canadian company, to utilize its patented cancer research compositions and methods.

Original source language: Federal Register — All DocumentsOpen original release →

Explore insights